These strategies offer novel therapeutics for hypercholesterolemia, as statins upregulate the expression of both LDLR and PCSK9, which may explain the relatively small incremental reduction in LDL-C with each doubling of the statin dose [44]. Here, PCSK9 is linked to familial hypercholesterolemia.